MLICM
CTMX icon

Metropolitan Life Insurance Company (MetLife)’s CytomX Therapeutics CTMX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,708
Closed -$12.6K – 2389
2022
Q1 		$12.6K Sell
4,708
-6,734
-59% -$25.9K ﹤0.01% 2229
2021
Q4 		$49.5K Buy
11,442
+4,796
+72% +$28.1K ﹤0.01% 2701
2021
Q3 		$33.8K Sell
6,646
-12,278
-65% -$65.7K ﹤0.01% 2796
2021
Q2 		$120K Buy
18,924
+2,569
+16% +$20K ﹤0.01% 2503
2021
Q1 		$126K Buy
16,355
+11,905
+268% +$94.2K ﹤0.01% 2318
2020
Q4 		$29.1K Sell
4,450
-9,990
-69% -$71.4K ﹤0.01% 2504
2020
Q3 		$96K Sell
14,440
-194
-1% -$1.44K ﹤0.01% 2242
2020
Q2 		$122K Buy
14,634
+5,858
+67% +$54.4K ﹤0.01% 2132
2020
Q1 		$67.3K Sell
8,776
-3,195
-27% -$22.3K ﹤0.01% 2268
2019
Q4 		$99.5K Sell
11,971
-6,711
-36% -$45.3K ﹤0.01% 2337
2019
Q3 		$138K Buy
18,682
+5,098
+38% +$50.3K ﹤0.01% 2124
2019
Q2 		$152K Buy
13,584
+1,575
+13% +$16.5K ﹤0.01% 2071
2019
Q1 		$129K Sell
12,009
-1,470
-11% -$21.7K ﹤0.01% 2174
2018
Q4 		$204K Buy
13,479
+562
+4% +$8.34K ﹤0.01% 1813
2018
Q3 		$239K Hold
12,917
– – ﹤0.01% 1886
2018
Q2 		$295K Buy
12,917
+3,432
+36% +$87.7K ﹤0.01% 1678
2018
Q1 		$270K Buy
9,485
+187
+2% +$5.34K ﹤0.01% 1695
2017
Q4 		$196K Sell
9,298
-7,878
-46% -$163K ﹤0.01% 1920
2017
Q3 		$312K Hold
17,176
– – ﹤0.01% 2007
2017
Q2 		$266K Hold
17,176
– – ﹤0.01% 2162
2017
Q1 		$297K Hold
17,176
– – ﹤0.01% 2005
2016
Q4 		$189K Hold
17,176
– – ﹤0.01% 2379
2016
Q3 		$269K Hold
17,176
– – ﹤0.01% 2141
2016
Q2 		$175K Buy
+17,176
New +$196K ﹤0.01% 2410

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CTMX Position: Q2 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 4,708 shares — an estimated $12.6K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CTMX in Q2 2016 and held it in 24 quarters. The position peaked at $312K in Q3 2017. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 4,708 CytomX Therapeutics shares in Q2 2022, an estimated $12.6K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in CytomX Therapeutics in Q2 2016 and held it in 24 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s CytomX Therapeutics position peaked at $312K in Q3 2017.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2022, filed 11 Aug 2022.